Atypical Spitzoid neoplasms: A review of potential markers of biological behavior including sentinel node biopsy

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 437-447

  McCormack, Christopher J ^a   Conyers, Rachel K ^d   Scolyer, Richard A ^e   Kirkwood, John ^f   Speakman, David ^a   Wong, Nick ^c,g   Kelly, John W ^b   Henderson, Michael A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g AUSTIN HOSPITAL   (Australia)

Author keywords

Melanocytic lesions of uncertain malignant potential; Melanoma; Sentinel node biopsy; Spitz nevi; Spitzoid

Indexed keywords

CYCLIN D1; FATTY ACID SYNTHASE; MELAN A; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN KINASE B; STEM CELL FACTOR RECEPTOR; TELOMERASE; TUMOR MARKER;

ATYPICAL SPITZ TUMOR; ATYPICAL SPITZOID TUMOR; CANCER PROGNOSIS; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CUTANEOUS MELANOMA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MALIGNANT TRANSFORMATION; MEDICAL TERMINOLOGY; MELANOCYTE; MELANOCYTIC LESION OF UNCERTAIN MALIGNANT POTENTIAL; MELANOCYTIC NEVUS; MELANOCYTOSIS; METASTATIC MELANOMA; MUTATION RATE; ONCOGENE C FOS; ONCOGENE C KIT; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE N RAS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; STANDARDIZATION; DIFFERENTIAL DIAGNOSIS; LYMPH NODE METASTASIS; MELANOMA; METABOLISM; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; PROGNOSIS; SKIN NEOPLASMS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA; PRECANCEROUS CONDITIONS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926074976     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000084     Document Type: Review

References (150)

1. Ludgate MW, Fullen DR, Lee J, Lowe L, Bradford C, Geiger J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer 2009;115:631-641.
2. Massi D, Cesinaro AM, Tomasini C, Paglierani M, Bettelli S, Dal Maso L, et al. Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. J Am Acad Dermatol 2011;64:919-935.
3. Tom WL, Hsu JW, Eichenfield LF, Friedlander SF. Pediatric 'STUMP' lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol 2011;64:559-572.
4. Da Forno PD, Fletcher A, Pringle JH, Saldanha GS. Understanding spitzoid tumours: new insights from molecular pathology. Br J Dermatol 2008;158:4-14.
5. Fullen DR, Poynter JN, Lowe L, Su LD, Elder JT, Nair RP, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006;19:1324-1332.
6. Van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005;29:1145-1151.
7. Mills OL, Marzban S, Zager JS, Sondak VK, Messina JL. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol 2012;39:331-336.
8. Barnhill RL, Argenyi ZB, From L, Glass LF, Maize JC, Mihm MC Jr, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30:513-520.
9. Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol 1999;135:282-285.
10. Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part I. Background and diagnoses. J Am Acad Dermatol 2011;65:1073-1084.
11. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol 2006;19(Suppl 2):S21-S33.
12. Abraham RM, Ming ME, Elder DE, Xu X. An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol 2012;39:21-24.
13. Lever WF, Elder DE. Lever's histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
14. Situm M, Bolanca Z, Buljan M, Tomas D, Ivancić M. Nevus Spitz - everlasting diagnostic difficulties - the review. Coll Antropol 2008;32(Suppl 2):171-176.
15. Spitz S. Melanomas of childhood. Am J Pathol 1948;24:591-609.
16. Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 1953;6:1-45.
17. Jang YH, Lee JY, Kim YC. Acral pigmented spitz nevus that clinically mimicked acral lentiginous malignant melanoma. Ann Dermatol 2011;23:246-249.
18. Ackerman AB. Spitz nevus. Am J Dermatopathol 1997;19:419-421.
19. Kamino H, Misheloff E, Ackerman AB, Flotte TJ, Greco MA. Eosinophilic globules in Spitz's nevi: new findings and a diagnostic sign. Am J Dermatopathol 1979;1:323-324.
20. Kernen JA, Ackerman LV. Spindle cell nevi and epithelioid cell nevi (socalled juvenile melanomas) in children and adults: a clinicopathological study of 27 cases. Cancer 1960;13:612-625.
21. Paniago-Pereira C, Maize JC, Ackerman AB. Nevus of large spindle and/or epithelioid cells (Spitz's nevus). Arch Dermatol 1978;114:1811-1823.
22. Sepehr A, Chao E, Trefrey B, Blackford A, Duncan LM, Flotte TJ, et al. Long-term outcome of Spitz-type melanocytic tumors. Arch Dermatol 2011;147:1173-1179.
23. Ferrara G, Argenziano G, Soyer HP, Chimenti S, Di Blasi A, Pellacani G, et al. The spectrum of Spitz nevi: a clinicopathologic study of 83 cases. Arch Dermatol 2005;141:1381-1387.
24. Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol 2010;34:314-326.
25. Barnhill RL, Flotte TJ, Fleischli M, Perez-Atayde A. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer 1995;76:1833-1845.
26. Cerroni L. Spitzoid tumors: a matter of perspective? Am J Dermatopathol 2004;26:1-3.
27. Dahlstrom JE, Scolyer RA, Thompson JF, Jain S. Spitz naevus: diagnostic problems and their management implications. Pathology 2004;36:452-457.
28. Mones JM, Ackerman AB. 'Atypical' Spitz's nevus, 'malignant' Spitz's nevus, and 'metastasizing' Spitz's nevus: a critique in historical perspective of three concepts flawed fatally. Am J Dermatopathol 2004;26:310-333.
29. Walsh N, Crotty K, Palmer A, McCarthy S. Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing histopathologic criteria. Hum Pathol 1998;29:1105-1112.
30. Barnhill RL, Gupta K. Unusual variants of malignant melanoma. Clin Dermatol 2009;27:564-587.
31. Ghazi B, Carlson GW, Murray DR, Gow KW, Page A, Durham M, et al. Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms. Ann Surg Oncol 2010;17:2471-2475.
32. Barnhill RL. The spitzoid lesion: the importance of atypical variants and risk assessment. Am J Dermatopathol 2006;28:75-83.
33. Gerami P, Cooper C, Bajaj S, Wagner A, Fullen D, Busam K, et al. Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol 2013;37:1387-1394.
34. Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002;26:47-55.
35. Zembowicz A, Carney JA, Mihm MC. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 2004;28:31-40.
36. Scolyer RA, Thompson JF, Warnke K, McCarthy SW. Pigmented epithelioid melanocytoma. Am J Surg Pathol 2004;28:1114-1115, author reply 1115-1116.
37. Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol 2009;161:364-372.
38. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014;5:3116.
39. Busam KJ, Murali R, Pulitzer M, McCarthy SW, Thompson JF, Shaw HM, et al. Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol 2009;33:1386-1395.
40. Mooi WJ, Krausz T. Spitz nevus versus spitzoid melanoma: diagnostic difficulties, conceptual controversies. Adv Anat Pathol 2006;13:147-156.
41. Bell ME, Hill DP, Bhargava MK. Lymphatic invasion in pigmented nevi. Am J Clin Pathol 1979;72:97-100.
42. Carson KF, Wen DR, Li PX, Lana AM, Bailly C, Morton DL, Cochran AJ. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20:834-840.
43. McCarthy SW, Palmer AA, Bale PM, Hirst E. Naevus cells in lymph nodes. Pathology 1974;6:351-358.
44. Biddle DA, Evans HL, Kemp BL, El-Naggar AK, Harvell JD, White WL, et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol 2003;27:673-681.
45. Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994;102:102-108.
46. Azzopardi JG, Ross CM, Frizzera G. Blue naevi of lymph node capsule. Histopathology 1977;1:451-461.
47. Bortolani A, Barisoni D, Scomazzoni G. Benign 'metastatic' cellular blue nevus. Ann Plast Surg 1994;33:426-431.
48. Carter BA. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000;113:259-265.
49. Henley JD, Jensen RA, Simpson JF, Page DL. Benign mullerian lymph node inclusions. An unusual case with implications for pathogenesis and review of the literature. Arch Pathol Lab Med 1995;119:841-844.
50. Parkash V, Vidwans M, Carter D. Benign mesothelial cells in mediastinal lymph nodes. Am J Surg Pathol 1999;23:1264-1269.
51. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008;25:100-111.
52. Mason A, Wititsuwannakul J, Klump VR, Lott J, Lazova R. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma. J Cutan Pathol 2012;39:1062-1074.
53. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg 1999;3:293-297.
54. Murali R, Sharma RN, Thompson JF, Stretch JR, Lee CS, McCarthy SW. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features (so-called atypical spitzoid tumors). Ann Surg Oncol 2008;15:302-309.
55. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer 2003;97:499-507.
56. Urso C, Borgognoni L, Saieva C, Ferrara G, Tinacci G, Begliomini B, Reali UM. Sentinel lymph node biopsy in patients with 'atypical Spitz tumors'. A report on 12 cases. Hum Pathol 2006;37:816-823.
57. Barnhill RL, Kutzner H, Schmidt B, Ali L, Bagot M, Janin A, Lugassy C. Atypical spitzoid melanocytic neoplasms with angiotropism: a potential mechanism of locoregional involvement. Am J Dermatopathol 2011;33:236-243.
58. Namikawa K, Yamazaki N, Nakai Y, Ihn H, Tomita Y, Uhara H, et al. Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan. J Dermatol 2012;39:130-137.
59. Hung T, Piris A, Lobo A, Mihm MC Jr, Sober AJ, Tsao H, et al. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol 2013;44:87-94.
60. Paradela S, Fonseca E, Pita-Fernández S, Prieto VG. Spitzoid and nonspitzoid melanoma in children. A prognostic comparative study. J Eur Acad Dermatol Venereol 2013;27:1214-1221.
61. Paradela S, Fonseca E, Pita S, Kantrow SM, Goncharuk VN, Diwan H, Prieto VG. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol 2009;36:740-752.
62. Pol-Rodriquez M, Lee S, Silvers DN, Celebi JT. Influence of age on survival in childhood spitzoid melanomas. Cancer 2007;109:1579-1583.
63. Ferrari A, Bono A, Baldi M, Collini P, Casanova M, Pennacchioli E, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115:649-654.
64. Gibbs P, Moore A, Robinson W, Walsh P, Golitz L, Gonzalez R. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol 2000;22:428-432.
65. Sander B, Karlsson P, Rosdahl I, Westermark P, Boeryd B. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. Int J Cancer 1999;80:646-651.
66. Kapur P, Selim MA, Roy LC, Yegappan M, Weinberg AG, Hoang MP. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Mod Pathol 2005;18:197-204.
67. Kanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1997;10:917-920.
68. Li LX, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2000;22:489-495.
69. Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol 2004;122:499-505.
70. Bergman R, Malkin L, Sabo E, Kerner H. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol 2001;44:500-504.
71. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol 2003;16:525-529.
72. Li LX, Scolyer RA, Ka VS, McKinnon JG, Shaw HM, McCarthy SW, Thompson JF. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol 2003;27:1197-1202.
73. Nagasaka T, Lai R, Medeiros LJ, Brynes RK, McCourty A, Harada T, Saddik M. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study. Am J Dermatopathol 1999;21:115-120.
74. Harvell JD, Bastian BC, Le Boit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol 2002;26:654-661.
75. Bergman R, Shemer A, Levy R, Friedman-Birnbaum R, Trau H, Lichtig C. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions. Am J Dermatopathol 1995;17:547-550.
76. King MS, Porchia SJ, Hiatt KM. Differentiating spitzoid melanomas from Spitz nevi through CD99 expression. J Cutan Pathol 2007;34:576-80.
77. Wititsuwannakul J, Mason AR, Klump VR, Lazova R. Neuropilin-2 as a useful marker in the differentiation between Spitzoid malignant melanoma and Spitz nevus. J Am Acad Dermatol 2013;68:129-137.
78. Kayton ML, La Quaglia MP. Sentinel node biopsy for melanocytic tumors in children. Semin Diagn Pathol 2008;25:95-99.
79. Al Dhaybi R, Agoumi M, Gagné I, McCuaig C, Powell J, Kokta V. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi. J Am Acad Dermatol 2011;65:357-363.
80. Hilliard NJ, Krahl D, Sellheyer K. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma. J Cutan Pathol 2009;36:753-759.
81. Rode J, Williams RA, Jarvis LR, Dhillon AP, Jamal O. S100 protein, neurone specific enolase, and nuclear DNA content in Spitz naevus. J Pathol 1990;161:41-45.
82. Ribe A, McNutt NS. S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol 2003;16:505-511.
83. Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 1999;113:1065-1069.
84. Ali L, Helm T, Cheney R, Conroy J, Sait S, Guitart J, Gerami P. Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms. Int J Clin Exp Pathol 2010;3:593-599.
85. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 2006;19:40-49.
86. Bastian BC, Olshen AB, Le Boit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003;163:1765-1770.
87. Bastian BC, Le Boit PE, Hamm H, Bröcker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-2175.
88. Takata M, Lin J, Takayanagi S, Suzuki T, Ansai S, Kimura T, et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol 2007;156:1287-1294.
89. Huynh KT, Takei Y, Kuo C, Scolyer RA, Murali R, Chong K, et al. Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. Br J Dermatol 2012;166:1319-1326.
90. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
91. Wiesner T, Murali R, Fried I, Cerroni L, Busam K, Kutzner H, Bastian BC. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012;36:818-830.
92. Mihic-Probst D, Perren A, Schmid S, Saremaslani P, Komminoth P, Heitz PU. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res 2004;24:2415-2418.
93. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004;111:705-710.
94. Lee DA, Cohen JA, Twaddell WS, Palacios G, Gill M, Levit E, et al. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Cancer 2006;106:907-913.
95. Bastian BC, Le Boit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000;157:967-972.
96. Isabel Zhu Y, Fitzpatrick JE. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. J Cutan Pathol 2006;33:33-37.
97. Penneys N, Seigfried E, Nahass G, Vogler C. Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol 1995;32:964-967.
98. Niemann TH, Argenyi ZB. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol 1993;15:441-445.
99. Bergman R, Azzam H, Sprecher E, Manov L, Munichor M, Friedman-Birnbaum R. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol 2000;42:496-500.
100. Stefanaki C, Stefanaki K, Antoniou C, Argyrakos T, Patereli A, Stratigos A, Katsambas A. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi. J Am Acad Dermatol 2007;56:815-824.
101. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, Robbins JB. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol 2007;34:593-596.
102. Bergman R, Lurie M, Kerner H, Kilim S, Friedman-Birnbaum R. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 1997;24:219-222.
103. Bergman R, Kerner H, Manov L, Friedman-Birnbaum R. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. Am J Dermatopathol 1998;20:262-265.
104. Fullen DR, Zhu W, Thomas D, Su LD. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol 2005;32:680-684.
105. Guttman-Yassky E, Bergman R, Manov L, Sprecher E, Shaefer Y, Kerner H. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas. J Cutan Pathol 2002;29:341-346.
106. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, Van Der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-724.
107. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
108. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-3079.
109. Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33:1146-1156.
110. Newman MD, Lertsburapa T, Mirzabeigi M, Mafee M, Guitart J, Gerami P. Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod Pathol 2009;22:989-995.
111. McCalmont TH. Fillet of FISH. J Cutan Pathol 2011;38:327-328.
112. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010;20:253-265.
113. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351-9358.
114. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004;95:962-968.
115. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-4022.
116. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006;66:6111-6117.
117. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
118. Thompson JF. The value of sentinel node biopsy in patients with primary cutaneous melanoma. Dermatol Surg 2008;34:550-554, discussion 554-555.
119. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
120. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
121. Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control 2009;16:225-233.
122. Kelley SW, Cockerell CJ. Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. J Am Acad Dermatol 2000;42:527-530.
123. Murakami M, Wada T, Kashiwagi T, Ishida-Yamamoto A, Iizuka H. Nodular malignant melanoma with Spitz nevus-like pathological features finally confirmed by the pathological feature of the sentinel lymph node. J Dermatol 2007;34:821-828.
124. Urso C. Atypical Spitz tumors: facts and opinions on intranodal melanocytes. Hum Pathol 2008;39:470 author reply 471.
125. Zuckerman R, Maier JP, Guiney WB Jr, Huntsman WT, Mooney EK. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy. Ann Plast Surg 2001;46:394-399.
126. Raskin L, Ludgate M, Iyer RK, Ackley TE, Bradford CR, Johnson TM, Fullen DR. Copy number variations and clinical outcome in atypical spitz tumors. Am J Surg Pathol 2011;35:243-252.
127. Gamblin TC, Edington H, Kirkwood JM, Rao UN. Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol 2006;13:1664-1670.
128. Le Boit PE. What do these cells prove? Am J Dermatopathol 2003;25:355-356.
129. Wick MR. Melanocytic lesions with features of Spitz nevus. Hum Pathol 2006;37:779-780.
130. Smith KJ, Barrett TL, Skelton HG 3rd, Lupton GP, Graham JH. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol 1989;13:931-9.
131. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol 2005;141:1016-1022.
132. Roaten JB, Partrick DA, Bensard D, Pearlman N, Gonzalez R, Fitzpatrick J, McCarter MD. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg 2005;40:988-992, discussion 992.
133. Livestro DP, Kaine EM, Michaelson JS, Mihm MC, Haluska FG, Muzikansky A, et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 2007;110:614-624.
134. Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, et al. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012;19:3888-3895.
135. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, et al. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 2011;253:1211-1215.
136. Busam KJ, Pulitzer M. Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors? Adv Anat Pathol 2008;15:253-262.
137. McArthur GJ, Banwell ME, Cook MG, Powell BW. The role of sentinel node biopsy in the management of melanocytic lesions of uncertain malignant potential (MUMP). J Plast Reconstr Aesthet Surg 2007;60:952-954.
138. Gurbuz Y, Apaydin R, Muezzinoʇlu B, Buyukbabani N. A current dilemma in histopathology: atypical spitz tumor or Spitzoid melanoma? Pediatr Dermatol 2002;19:99-102.
139. Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg 2005;40:232-235.
140. Pacella SJ, Lowe L, Bradford C, Marcus BC, Johnson T, Rees R. The utility of sentinel lymph node biopsy in head and neck melanoma in the pediatric population. Plast Reconstr Surg 2003;112:1257-1265.
141. Urso C, Gelli R, Borgognoni L, Tinacci G, Reali UM. Positive sentinel node biopsy in a 30-month-old boy with atypical Spitz tumour (Spitzoid melanoma). Histopathology 2006;48:884-886.
142. Urso C, Borgognoni L, Doria M, Tinacci G, Zini E. Non-sentinel lymph node involvement in a patient with an atypical Spitz tumor and a positive sentinel node. Report of a case and review of the literature. J Cutan Pathol 2009;36:586-590.
143. Meyers MO, Yeh JJ, Deal AM, Byerly FL, Woosley JT, Frank J, et al. Age and Breslow depth are associated with a positive sentinel lymph node in patients with cutaneous melanocytic tumors of uncertain malignant potential. J Am Coll Surg 2010;211:744-748.
144. Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part II. Natural history and management. J Am Acad Dermatol 2011;65:1087-1092.
145. Gow KW, Rapkin LB, Olson TA, Durham MM, Wyly B, Shehata BM. Sentinel lymph node biopsy in the pediatric population. J Pediatr Surg 2008;43:2193-2198.
146. Magro CM, Crowson AN, Mihm MC Jr, Gupta K, Walker MJ, Solomon G. The dermal-based borderline melanocytic tumor: a categorical approach. J Am Acad Dermatol 2010;62:469-479.
147. Cochran AJ, Binder S, Morton DL. The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. J Cutan Pathol 2010;37(Suppl 1):54-59.
148. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007;25:1363-1368.
149. Pasquali S, Van Der Ploeg AP, Mocellin S, Stretch JR, Thompson JF, Scolyer RA. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res 2013;26:326-337.
150. Kuphal S, Bosserhoff A. miR networks in melanoma - more to come! Pigment Cell Melanoma Res 2013;26:292-293.